Form 4: BioAffinity Technologies VP and CFO, James Michael Edwards, Reports Stock Grant and Resulting Ownership

James Michael Edwards, VP and CFO of bioAffinity Technologies, reports the acquisition of 6,172 shares of common stock through a grant and the resulting adjusted beneficial ownership.

Summary

• On January 10, 2025, James Michael Edwards, the VP and CFO of bioAffinity Technologies, acquired 6,172 shares of common stock through a grant.
• These shares were acquired at a price of $0.
• Following this transaction, Edwards's beneficial ownership of common stock is 120,128 shares.
• The grant of restricted shares vests pro rata on a monthly basis for 12 months, starting February 10, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock ownership change. The grant itself could be seen as mildly positive, reflecting an incentive for the executive.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies a continued relationship between the executive and the company for at least 12 months.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the ownership structure and management's stake in the company.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a key executive.

Key Dates

Keywords

bioAffinity Technologies, James Michael Edwards, BIAF, Form 4, Beneficial Ownership, Stock Grant, Restricted Shares, Insider Trading